Streetbeat News

Price Targets

JNJ

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Johnson & Johnson (NYSE:JNJ) and maintained a price target of $215.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:22 pm

BL

NIO

PRME

Nio shares rise 15% due to a significant investment in its China subsidiary. Prime Medicine enters a strategic collaboration with Bristol Myers Squibb, receiving $110M upfront and potential milestones over $3.5B, boosting its stock by 33%. BlackLine shares increase after a Morgan Stanley upgrade.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

INZY

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

CMG

Oppenheimer analyst Brian Bittner has reiterated an Outperform rating on Chipotle Mexican Grill (NYSE:CMG) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm

AQST

Leerink Partners has reiterated its Outperform rating on Aquestive Therapeutics and raised the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:08 pm

CHTR

Wolfe Research has downgraded Charter Communications from Peer Perform to Underperform, setting a price target of $300.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:08 pm

PR

16 analysts have provided varied opinions on Permian Resources (NYSE:PR) over the past quarter, with a mix of bullish and somewhat bullish ratings. The average 12-month price target has declined by 5.63% to $18.94. Analysts have adjusted their ratings and price targets in response to market dynamics, with some lowering their targets. Permian Resources has shown strong financial performance with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm

AQST

HC Wainwright & Co. has maintained a Buy rating on Aquestive Therapeutics and raised the price target from $9 to $10, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:55 am

BL

BlackLine shares rose following an upgrade by Morgan Stanley from Equal-Weight to Overweight, with a price target increase from $60 to $70.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:53 am

META

Monness, Crespi, Hardt analyst Brian White maintains a Buy rating on Meta Platforms and raises the price target from $570 to $620.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:53 am